Empagliflozin after Acute Myocardial Infarction.
Javed ButlerW Schuyler JonesJacob A UdellStefan D AnkerMark C PetrieJosephine HarringtonMichaela MattheusIsabella ZwienerOffer AmirM Cecilia BahitJohann BauersachsAntoni Bayes-GenisYundai ChenVijay K ChopraGemma FigtreeJunbo GeShaun G GoodmanNina GotchevaShinya GotoTomasz GasiorWaheed JamalJames L JanuzziMyung Ho JeongYuri LopatinRenato D LopesBéla MerkelyPuja B ParikhAlexander ParkhomenkoPiotr PonikowskiXavier RosselloMorten SchouDragan SimicPhillippe Gabriel StegJoanna SzachniewiczPeter van der MeerDragos VinereanuShelley ZierothMartina BrueckmannMikhail SuminDeepak L BhattAdrian F HernandezPublished in: The New England journal of medicine (2024)
Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, NCT04509674.).